Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;24(10):1781-4.
doi: 10.1038/leu.2010.154. Epub 2010 Aug 12.

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

P M Bhende, S I Park, M S Lim, D P Dittmer, B Damania

The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma

P M Bhende et al. Leukemia. 2010 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflict of interest

Figures

Figure 1
Figure 1. NVP-BEZ235 inhibits the growth of various follicular lymphoma cell lines by targeting the PI3K-Akt-mTOR-S6K pathway
a. Follicular lymphoma cell lines SUDHL16, K422, and FL-18 (13) were treated with either DMSO or NVP-BEZ235 (25 nM or 50 nM) for the indicated times. MTS readings were taken at 0, 1, 2 and 3 days using the Cell Titer 96® AQueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer’s instructions. Absorbance was measured at 485 nm. The absorbance at 485 nm is depicted on the y-axis and time in days is shown on the x-axis. All samples were done in triplicate and standard deviation for each time point is shown. b. SUDHL4, SUDHL16, FL-18 and K422, were treated with 25nM NVP-BEZ235 for either 16 or 24 hours. Cells were harvested, lysed, and immunoblots were performed for total Akt, mTOR, GSK3β, and S6K, and their phosphorylated forms: p-Akt(Ser473), p-mTOR(Ser2448), p-GSK3b(Ser9) and p-S6K(Thr421/Ser424). The phosphorylation sites are indicated in parentheses. All antibodies were purchased from Cell Signaling.
Figure 2
Figure 2. Treatment with NVP-BEZ235 inhibits tumor growth in FL mouse xenograft model by targeting the PI3K-Akt-mTOR-S6K pathway
a. FL-18 cells were treated with various concentrations of NVP-BEZ235 for 72 hours. The IC50 for FL-18 growth inhibition was calculated at 6.59nM. b. FL-18 and SUDL16 cells were treated with either DMSO or 25 nM NVP-BEZ235 for 24 hours after which cells were harvested and subjected to a caspase-3 activation assay (Promega). The increase in caspase-3 activation in the NVP-BEZ235-treated cells compared to cells incubated with vehicle control is shown on the Y-axis. c. Treatment of FL-18 tumors with NVP-BEZ235 suppressed tumor growth in vivo. Tumor volume is depicted on the y-axis and time in days is shown on the x-axis. All animal procedures were performed in accordance with the UNC-CH IACUC. Briefly, NOD.CB17-Prkdcscid/J or 4-5-week-old athymic nude-Foxn1ˆnu female mice were injected with anti-asialo GM1 antibody (Wako) intraperitoneally. Twenty four hours later, the mice were subcutaneously injected 1×107 or 1×106 FL-18 cells per mouse. Treatment with NVP-BEZ235 or vehicle was started upon the development of palpable tumors. NVP-BEZ235 was dissolved in a 1:9 v/v mixture of 1-methyl-2-pyrrolidone (Fluka) and polyethylene glycol 300 (Sigma). A dose of 45 mg/kg or equal volume of the vehicle was administered orally 5-6 days per week as previously described (11). A total of eighteen mice were treated with NVP-BEZ235, and seventeen mice were treated with vehicle. Tumor volume (LxWxD) was calculated daily and animals were sacrificed when the tumor volumes of control mice reached the maximum allowed by IACUC. Tumors were excised from mice, fixed and sectioned. d. Immunohistochemistry of tumors from vehicle- and NVP-BEZ235-treated mice. Tumors were fixed, sectioned, and stained with the antibodies against phospho-S6K and phospho-Akt (S473) described previously (10). Images are shown at 400X magnification. Sections stained without primary antibody served as a negative control.
See this image and copyright information in PMC

References

    1. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med. 1982 Nov 11;307(20):1231–1236. - PubMed
    1. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993 Oct 15;82(8):2289–2295. - PubMed
    1. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993 Oct 1;82(7):1994–2004. - PubMed
    1. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 Dec 1;106(12):3725–3732. - PubMed
    1. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007 Jun 29;129(7):1261–1274. - PMC - PubMed

Publication types

MeSH terms